Entecavir Tablets 0.5mg [SANDOZ] (Entecavir Tablets [SANDOZ]® / エンテカビル錠0.5mg「サンド」)

JPY ¥7,600

Japanese Antiviral Chemotherapeutic Agent (Entecavir Hydrate 0.5mg). Oral tablet for suppression of HBV replication in chronic hepatitis B. 70 tablets [14 tablets (PTP) x 5]. Mfd. by Sandoz K.K., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥6,992
10 - 19 12% JPY ¥6,688
20 + 18% JPY ¥6,232
SKU: ENT-05-TAB Category:

Description

Product Overview / 商品概要

Entecavir Tablets 0.5mg [SANDOZ] (エンテカビル錠0.5mg「サンド」)
Generic: Entecavir Hydrate / エンテカビル水和物
Therapeutic Category: Antiviral Chemotherapeutic Agent / 抗ウイルス化学療法剤
Manufactured by: Sandoz K.K. / サンド株式会社

Composition & Specification / 組成・規格

Active Ingredient: Entecavir Hydrate 0.53mg (equivalent to Entecavir 0.5mg) per tablet / 1錠中 エンテカビル水和物0.53mg(エンテカビルとして0.5mg)
Additives: Lactose hydrate, Microcrystalline cellulose, Crospovidone, Magnesium stearate, Hypromellose, Macrogol 6000 EP, Titanium dioxide, Talc / 乳糖水和物、結晶セルロース、クロスポビドン、ステアリン酸マグネシウム、ヒプロメロース、マクロゴール6000EP、酸化チタン、タルク
Appearance: White, round, film-coated tablet. Diameter: 8.2mm, Thickness: 4.2mm, Weight: 210mg. Identification code (PTP): Sz ETV
外観: 白色円形のフィルムコーティング錠。直径8.2mm、厚さ4.2mm、質量210mg。識別コード(PTP): Sz ETV

Indications / 効能効果

EN: Suppression of hepatitis B virus (HBV) replication in chronic hepatitis B with confirmed abnormal liver function associated with HBV replication
JA: B型肝炎ウイルスの増殖を伴い肝機能の異常が確認されたB型慢性肝疾患におけるB型肝炎ウイルスの増殖抑制

Dosage and Administration / 用法用量

EN: Administer orally on an empty stomach (at least 2 hours after a meal and at least 2 hours before the next meal). The usual adult dose is 0.5mg of entecavir once daily. For lamivudine-refractory patients (those with detectable HBV viremia during lamivudine therapy or harboring lamivudine-resistant mutant virus), 1mg of entecavir once daily is recommended.
JA: 本剤は、空腹時(食後2時間以降かつ次の食事の2時間以上前)に経口投与する。通常、成人にはエンテカビルとして0.5mgを1日1回経口投与する。なお、ラミブジン不応(ラミブジン投与中にB型肝炎ウイルス血症が認められる又はラミブジン耐性変異ウイルスを有するなど)患者には、エンテカビルとして1mgを1日1回経口投与することが推奨される。

Contraindications / 禁忌

EN: Patients with a history of hypersensitivity to any component of this product
JA: 本剤の成分に対し過敏症の既往歴のある患者

Regulatory Information / 規制情報

Approval No.: 22900AMX00160000
Sales Started: June 2017 / 2017年6月
Classification Code: 87625
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年

Packaging / 包装

Main Package (for sale): 70 tablets [14 tablets (PTP) x 5] / 70錠[14錠(PTP)×5]
Other Available Packages (by special order): 70 tablets [14 tablets (PTP) x 5]

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Entecavir Tablets 0.5mg [SANDOZ] (Entecavir Tablets [SANDOZ]® / エンテカビル錠0.5mg「サンド」)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Entecavir Tablets 0.5mg [SANDOZ] (Entecavir Tablets [SANDOZ]®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.